- Home
- CANF vs HIND Comparison
CANF vs HIND Comparison
Compare CANF & HIND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- HIND
- Stock Information
- Founded
- CANF 1994
- HIND N/A
- Country
- CANF Israel
- HIND United States
- Employees
- CANF N/A
- HIND N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- HIND
- Sector
- CANF Health Care
- HIND
- Exchange
- CANF Nasdaq
- HIND Nasdaq
- Market Cap
- CANF 9.6M
- HIND 10.3M
- IPO Year
- CANF N/A
- HIND 2016
- Fundamental
- Price
- CANF $0.39
- HIND $5.28
- Analyst Decision
- CANF Strong Buy
- HIND
- Analyst Count
- CANF 3
- HIND 0
- Target Price
- CANF $10.50
- HIND N/A
- AVG Volume (30 Days)
- CANF 204.7K
- HIND N/A
- Earning Date
- CANF 11-27-2025
- HIND N/A
- Dividend Yield
- CANF N/A
- HIND N/A
- EPS Growth
- CANF N/A
- HIND N/A
- EPS
- CANF N/A
- HIND N/A
- Revenue
- CANF $560,000.00
- HIND N/A
- Revenue This Year
- CANF $461.72
- HIND N/A
- Revenue Next Year
- CANF N/A
- HIND N/A
- P/E Ratio
- CANF N/A
- HIND N/A
- Revenue Growth
- CANF N/A
- HIND N/A
- 52 Week Low
- CANF $0.37
- HIND N/A
- 52 Week High
- CANF $2.35
- HIND N/A
- Technical
- Relative Strength Index (RSI)
- CANF 20.76
- HIND 42.28
- Support Level
- CANF $0.37
- HIND $5.16
- Resistance Level
- CANF $0.42
- HIND $6.56
- Average True Range (ATR)
- CANF 0.02
- HIND 0.34
- MACD
- CANF 0.00
- HIND 0.00
- Stochastic Oscillator
- CANF 14.33
- HIND 11.74
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).